Single-chain Fv antibodies for targeting cancer therapy.
Begent
R H
RH
CRC Targeting and Imaging Group, Royal Free Hospital School of Medicine, London, U.K.
Chester
K A
KA
D000818:Animals; D002272:Carcinoembryonic Antigen / Q000276:immunology; D006801:Humans; D007128:Immunoglobulin Fragments / Q000096:biosynthesis / Q000627:therapeutic use*; D007135:Immunoglobulin Variable Region / Q000096:biosynthesis; D007167:Immunotherapy; D009369:Neoplasms / Q000628:therapy*; D009374:Neoplasms, Experimental / Q000628:therapy; D011993:Recombinant Fusion Proteins / Q000096:biosynthesis / Q000627:therapeutic use; D011623:gamma-Glutamyl Hydrolase / Q000096:biosynthesis / Q000627:therapeutic use
D002272:Carcinoembryonic Antigen; D007128:Immunoglobulin Fragments; D007135:Immunoglobulin Variable Region; D011993:Recombinant Fusion Proteins; C055966:immunoglobulin Fv; D011623:gamma-Glutamyl Hydrolase